BIOPHARMX CORP. news, videos and press releases - Page 5
For more news please use our advanced search feature.
BIOPHARMX CORP. - More news...
BIOPHARMX CORP. - More news...
- BioPharmX Reports First Quarter 2018 Financial Results
- BioPharmX to Report First Quarter Financial Results
- BioPharmX Advances BPX-01 2% Upon Achieving Statistical Significance for Primary Endpoint
- BioPharmX to Host "State of Acne" Symposium on June 1
- BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acne
- BioPharmX Announces Closing of $5.0 Million Offering
- BioPharmX Announces $5.0 Million Offering
- BioPharmX Completes Last Subject Visit in its Phase 2b Trial of BPX-01, Expects to Report Topline Results First Half of May 2017
- BioPharmX AACR Poster Will Present Findings Suggesting Molecular Iodine Inhibits Breast Cancer Cell Growth and Drives Cancer Cell Death
- BioPharmX Reports Fourth Quarter and Full Year 2017 Financial Results
- BioPharmX to Report Fourth Quarter and Full Year Financial Results
- BioPharmX Society of Toxicology Poster Suggests Promise of BPX-01 as Topical Acne Therapy, Highlights Safety
- BioPharmX to Present at 29th Annual ROTH Conference
- BioPharmX Presents Poster at American Academy of Dermatology Annual Meeting Suggesting BPX-01 Safely, Efficiently Delivers Acne-Fighting Minocycline to Pilosebaceous Units
- Specialty Pharma Industry Veteran Charles Gregory Vontz Joins BioPharmX Board of Directors
- BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
- BioPharmX Completes Enrollment of BPX-01 Phase 2b OPAL Clinical Trial for Acne Vulgaris
- BioPharmX Corporation Reports Third Quarter Financial Results
- BioPharmX to present evidence that BPX-01 topical minocycline gel may reduce acne-associated inflammation
- BioPharmX to Report Third Quarter Financial Results
- BioPharmX Presents Research at Cell Biology 2016 Showing How Molecular Iodine Promotes Breast Health by Attacking Fibrocystic Breast Tissue
- BioPharmX Corporation Announces Closing of a $12.5 Million Unit Offering
- BioPharmX Corporation Announces Pricing of Unit Offering
- BioPharmX Presents BPX-01 Topical Minocycline Gel Acne Data at SDEF's 17th Annual Las Vegas Dermatology Seminar
- BioPharmX Studies Suggest its Violet® Iodine Formulation Inhibits Growth of Both FBC and Common Breast Cancer Cells in vitro
- BioPharmX Announces Registered Direct Offering
- BioPharmX Corporation Reports Second Quarter Financial Results
- BioPharmX to Report Second Quarter Financial Results on September 12, 2016
- BioPharmX to Report Fourth Quarter and Full Year Financial Results on April 26, 2016